Source

2011/785/EU: Commission Implementing Decision of 28 November 2011 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2011) 7382) Text with EEA relevance

Decision 2008/911/EC · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annexes I and II of Decision 2008/911/EC are amended in accordance with the Annex to this Decision.

Article 2

Open ↗

This Decision is addressed to the Member States.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Annexes I and II to Decision 2008/911/EC are amended as follows: 1. in Annex I, the following substance is inserted after Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (sweet fennel fruit): ‘ Hamamelis virginiana L., folium et cortex aut ramunculus destillatum ’; 2. in Annex II, the following is inserted after the entry relating to Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus: ‘ COMMUNITY LIST ENTRY ON HAMAMELIS VIRGINIANA L., FOLIUM ET CORTEX AUT RAMUNCULUS DESTILLATUM Scientific name of the plant Hamamelis virginiana L. Botanical family Hamamelidaceae Herbal preparation(s) 1. Distillate prepared from fresh leaves and bark (1:1.12 – 2.08; extraction solvent ethanol 6 % m/m) 2. Distillate prepared from dried twigs (1:2; extraction solvent ethanol 14-15 %) ( *1 ) European pharmacopoeia monograph reference Not applicable Indication(s) Indication (a) Traditional herbal medicinal product for relief of minor skin inflammation and dryness of the skin. Indication (b) Traditional herbal medicinal product to be used for the temporary relief of eye discomfort due to dryness of the eye or to exposure to wind or sun. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. Type of tradition European Specified strength Please see ‘Specified posology’. Specified posology Children over six years of age, adolescents, adults and elderly Indication (a) Distillate in a strength corresponding to 5-30 % in semi-solid preparations, several times daily. The use in children under six years of age is not recommended (see section ‘Special warnings and precautions for use’). Adolescents, adults and elderly Indication (b) Eye drops ( *2 ) Distillate (2) diluted (1:10), 2 drops/each eye, 3-6 times daily. The use in children under 12 years of age is not recommended (see section ‘Special warnings and precautions for use’). Route of administration Cutaneous use. Ocular use. Duration of use or any restrictions on the duration of use Children over six years of age, adolescents, adults and elderly Indication (a) If the symptoms persist longer than two weeks during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted. Adolescents, adults and elderly Indication (b) The recommended duration of use is four days. If the symptoms persist longer than two days during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance. Special warnings and precautions for use Indication (a) The use in children under six years of age has not been established due to lack of adequate data. Indication (b) If eye pain, changes in vision, continued redness, or irritation of the eye is experienced, or if the condition worsens or persists for more than 48 hours during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted. The use in children under 12 years of age has not been established due to lack of adequate data. For extracts containing ethanol, the appropriate labelling for ethanol, taken from the ‘Guideline on excipients in the label and package leaflet of medicinal products for human use’, must be included. Interactions with other medicinal products and other forms of interaction None reported. Pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Indication (a) Allergic contact dermatitis may occur in sensitive patients. The frequency is not known. Indication (b) Conjunctivitis cases have been reported. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars [if necessary] Not applicable. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [if necessary for the safe use of the product] Not applicable. ( *1 ) According to USP (USP-31- NF 26, 2008 Vol 3:3526)." ( *2 ) The medicinal product complies with the Ph. Eur. monograph on eye preparations (01/2008:1163).’." ( *1 ) According to USP (USP-31- NF 26, 2008 Vol 3:3526). ( *2 ) The medicinal product complies with the Ph. Eur. monograph on eye preparations (01/2008:1163).’.’

Other acts of the same type

Commission Decision (EU) 2018/563 of 20 November 2017 on State aid SA.34308 (2013/C) (ex 2013/NN) implemented by the Hellenic Republic for Hellenic Defence Systems S.A. (EAS — Ellinika Amyntika Systimata) (notified under document C(2017) 7361) (Text with EEA relevance. )Council Decision (Euratom) 2020/971 of 20 November 2017 approving the conclusion by the European Commission, on behalf of the European Atomic Energy Community, of the Comprehensive and Enhanced Partnership Agreement between the European Union and the European Atomic Energy Community and their Member States, of the one part, and the Republic of Armenia, of the other part Decision Council Implementing Decision (EU) 2017/2170 of 15 November 2017 on subjecting N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) to control measures Decision (EU) 2017/2192 of the European Parliament and of the Council of 15 November 2017 on the mobilisation of the European Globalisation Adjustment Fund following an application from Italy — EGF/2017/004 IT/Almaviva Council Decision (CFSP) 2017/2073 of 13 November 2017 amending Common Position 2001/931/CFSP on the application of specific measures to combat terrorism Council Decision (CFSP) 2017/2074 of 13 November 2017 concerning restrictive measures in view of the situation in Venezuela Decision of the Authority for European political parties and European political foundations of 13 November 2017 not to register Identités & traditions européennes Commission Implementing Decision (EU) 2017/2077 of 10 November 2017 amending Decision 2005/50/EC on the harmonisation of the 24 GHz range radio spectrum band for the time-limited use by automotive short-range radar equipment in the Community (notified under document C(2017) 7374) (Text with EEA relevance. )Commission Implementing Decision (EU) 2017/2078 of 10 November 2017 authorising an extension of use of yeast beta-glucans as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 7391)Commission Implementing Decision (EU) 2017/2079 of 10 November 2017 authorising the placing on the market of taxifolin-rich extract as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 7418)Council Decision (EU) 2017/2105 of 10 November 2017 on the position to be adopted on behalf of the European Union within the Trade Committee regarding the amendment of Annex XII of the Trade Agreement between the European Union and its Member States, of the one part, and Colombia and Peru, of the other part, setting out the list of Colombian procuring entities in accordance with the provisions of Title VI (‘Government Procurement’)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview